2026 Biotech Trends Outlook: From Innovation Narrative to Value Realization

Source: Stifel

In 2026, biotechnology will no longer rely solely on "storytelling" but will enter a new era driven by scientific research achievements and data. New therapies are maturing at an accelerated pace, with positive data emerging in the fields of oncology, metabolic diseases, and neuroscience. Technical pathways and treatment methods are also becoming increasingly diverse. However, capital remains cautious. According to Stifel's latest biotechnology outlook report: facing the upcoming patent cliff, large pharmaceutical companies are prioritizing assets that are scalable, can be quickly commercialized, and seamlessly integrated into existing product lines, rather than high-risk, hard-to-validate exploratory projects. Notably, Stifel specifically highlighted China: it is transitioning from a manufacturing and generic drug base to a new supply source for global innovative assets. Standing at the starting point of 2026, the biotechnology industry is ushering in a new wave of value realization.

Source: Stifel Biotechnology Outlook Report

1. Warmth Begins to Show, the Cliff Still Remains

The biopharmaceutical industry in 2026 still hasn't emerged from the dilemma of patent expirations.

Stifel Report Points Out That Over 40% of Large MNCs Will Face Patent Expiration Risks in the Next Six Years. MNCs Have Also Started Preparing Early — M&A Transactions Were Booming in the Second Half of 2025, and ING Predicts This Trend Will Accelerate by 15% in 2026!

PwC's 2026 Deal Outlook Points Out: These deal approaches are shifting focus to "precision-driven" rather than casting a wide net. BD deals tend to favor projects with clearer clinical or commercial prospects.

Recently, GSK spent $2.2 billion to acquire RAPT Therapeutics, obtaining assets in the fields of immunology and allergy. This is a typical case of preparing for the expiration of the core HIV drug Dolutegravir patent in 2028.To diversify risks, GSK adopts a two-pronged approach: accelerating the advancement on one handNew Long-Acting Injectable HIV Therapy (e.g., Cabenuva) Replacement, on the other hand, throughForeignDepartment M&AExpand new growth curves in immunology and beyond.

Capital Markets See Selective Recovery. U.S. Biotech IPOs Hit a More-than-Decade Low in 2025, with a Potential Rebound in 2026. On January 12, Aktis Oncology, a U.S.-based radiopharmaceutical company, kicked off the biotech IPO season by raising $318 million—surpassing expectations—and successfully going public, becoming a recovery bellwether.

2. The Next Battle for Weight Loss Drugs Begins

Towards 2026, GLP-1 Is No Longer the Only Answer in Obesity Treatment: Multi-Target and New Mechanisms Emerge – Who Will Take the Lead in the Next Era of Weight-Loss Drugs?

Stifel Report Predicts $200 Billion Potential for Obesity Treatment Market: The Driving Force Lies Not in Niche Markets or High-Priced Drugs, but in Future Universal Treatment Solutions That Can Be Used Long-Term by Large Populations and Are Widely Affordable for Healthcare Systems.

Under this huge cake, large MNCs have sparked a new wave of trading fever.

By the end of 2025, Pfizer acquired Metsera for approximately $10 billion and quickly initiated Phase III clinical trials for the acquired assets. Novo Nordisk joined the bidding war for Metsera, reflecting the intensifying competition for assets in the metabolic field. Apart from massive acquisitions, Novo Nordisk signed a $2.2 billion licensing agreement with Septerna, and Roche struck a $5.3 billion obesity collaboration with Zealand Pharma, actively expanding their metabolic drug R&D pipelines rather than solely chasing a single blockbuster product. Meanwhile, Corxel’s recent completion of a $287 million Series D financing round suggests promising prospects for differentiated oral drug solutions.

At the clinical level, the competition for convenient drug administration methods has never stopped. The Phase III clinical trial of orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist, showed that it achieved statistically and clinically significant weight loss in obese adult patients over 72 weeks. Compared with injectable peptide drugs, the oral regimen is expected to expand the application scope and improve convenience.

Production capacity is also regarded as a competitive weapon. Reuters particularly highlighted Eli Lilly's multi-year expansion plan for its production facilities, which aims to meet global demand and support its expansion into new markets.

More oral incretin-based therapies need to be closely watched in 2026.（amylin）Drug Data Release, GLP-1 Combination Therapy, and Emerging Mechanisms for Muscle Protection, Such as High-Quality Weight Loss Strategies Targeting ActRII. Next-Generation High-Quality Weight Loss "Top Contender": ActRII Target

3. New Mission of AI in Drug Development

By 2026, the most prominent artificial intelligence (AI) topics in the biopharmaceutical field will focus on the critical roles AI plays in the drug development process. The application focus is shifting from accelerating drug discovery to reshaping the structure of clinical projects, including trial design, patient stratification, endpoint evaluation, evidence generation, and validation.

In 2025, the U.S. FDA released a draft guidance on the use of AI to assist regulatory decision-making, clearly positioning AI as a tool that requires reasonable justification for specific application scenarios, with its validation level being proportional to the risk involved. This framework encourages sponsors to move away from broad claims about AI applications and toward auditable and controlled use cases. In December 2025, the FDA approved the first AI-based drug development tool, AIM-NASH, designed to standardize liver biopsy assessments in MASH trials.

At the same time, this field needs to face the test of time. Isomorphic Labs, supported by Google, expects its first clinical trial to start by the end of 2026, later than initially anticipated. This delay is not a failure of artificial intelligence but serves as a reminder: converting models into clinically usable assets still requires the cooperation of chemistry, toxicology, manufacturing, and regulatory processes—work that cannot be compressed like software development cycles. In January 2026, Isomorphic announced a new research collaboration with Johnson & Johnson, indicating that large pharmaceutical companies still wish to retain options regarding AI-native capabilities but now hold more realistic expectations about areas where AI can accelerate decision-making.

In 2026, it is necessary to focus on empirical evidence of AI enhancing R&D outcomes rather than merely optimizing discovery efficiency.

4: CGT Industrialization Faces Business Model Squeeze

In 2026, Cell and Gene Therapy (CGT) is facing a gap between clinical efficacy and operational feasibility. Analysis by the Boston Consulting Group points out that the challenges encountered by CAR-T and gene therapies after approval are not due to insufficient efficacy but rather the complex manufacturing processes, logistics distribution, and access barriers, which have slowed down the application process and increased costs.

Investor enthusiasm for gene therapy is cooling.

Recently, Novo Nordisk announced that it has entered a new phase of collaboration with Aspect Biosystems, revising the previous agreement on diabetes cell therapy and adjusting the roles of both parties."Swap"——Novo Nordisk has decided to cease independently building and operating its cell therapy division. Instead, it will transfer the rights to its stem cell-derived islet cells and hypoimmune cell technologies to Aspect, allowing the latter to lead the research, development, production, and commercialization processes. Meanwhile, Novo Nordisk retains the right to participate in subsequent projects through equity, milestone payments, and royalties. This move reflects that Novo Nordisk is gradually stepping away from the practical execution of CGT, proactively shedding operational burdens rather than attempting to internalize all aspects of the collaborative model.

5. In 2026, the biotechnology industry moves forward steadily

The biotech industry in 2026 is neither losing momentum nor skyrocketing, but moving forward steadily and intricately.

The regulatory framework is becoming clearer, capital more discerning, and competition fiercer, yet technological iteration has never slowed down. Innovation has shifted from an "expansion narrative" to a "realization narrative," moving from the pursuit of quantity to the pursuit of quality.

Whether it's the new metabolic mechanisms following GLP-1, breakthroughs in next-generation IO technology, or the deep integration of AI, all are driving the biotechnology industry to break through new ceilings.

The industry may no longer chase after quick glory, but it is ushering in a longer-term, more stable, and more sustainable growth curve.

Reference: Industry Research Report

       Title: 2026 Biotechnology Trend Forecast | Industry Research Report